Regeneron Pharmaceuticals(REGN)
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
Mock data
Subscribe for the real data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Dupixent | Dupilumab | 2017-03-28 | ||
| Evkeeza | Evinacumab | 2021-02-11 | ||
| Eylea | Aflibercept | 2011-11-18 | ||
| Inmazeb | Atoltivimab, Maftivimab, Odesivimab | 2020-10-14 | — | |
| Libtayo | Cemiplimab | 2018-09-28 | ||
| Praluent | Alirocumab | 2015-07-24 | ||
| Rilonacept regeneron (previously arcalyst) | Rilonacept | 2009-10-23 | ||
| Veopoz | Pozelimab | 2023-08-18 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
10
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use